神州细胞 (688520.SH) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−65.2x

Market Cap

CNY 17.12B

MomentumView details →

1D Return

−3.96%

YTD Return

—

RSI (14)

41.1

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−65.2x

Market Cap

CNY 17.12B

RSI (14)

41.1

MomentumView details →

1D Return

−3.96%

YTD Return

—

ProfitabilityView details →

Gross Margin

91.58%

Net Margin

−58.98%

EBITDA Margin

−19.57%

ROE (TTM)

−94.89%

ROA (TTM)

−17.74%

Asset Turnover

0.33x

GrowthView details →

Revenue YoY

−43.65%

EPS YoY

—

FCF YoY

−12.67%

Revenue CAGR 3Y

+15.10%

EPS CAGR 3Y

—

EBITDA YoY

—

EarningsView details →

EPS (Actual)

−CNY 0.40

EPS Surprise

—

Beats (12Q)

—

Next Q EPS Est

CNY 0.00

Avg Surprise (4Q)

—

Rev Surprise

0.00%

Capital & dividendView details →

Debt/Equity

3.06x

Current Ratio

0.98x

Quick Ratio

0.85x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

Financials snapshotView financials →

Revenue (TTM)

1.36B

Net Income (TTM)

−804.31M

Op. CF (TTM)

−261.57M

Next earningsOct 23, 2026 →

Latest newsMore news →

SinoCell Technologies reported a net loss of 366 million yuan for the first half of 2026, compared with a loss of 33.77 million yuan in the same period of 2025.7d ago

Sinocelltech's controlled subsidiary Sinocelltech Engineering received approval from China's National Medical Products Administration to conduct clinical trials for its SCTB10 injection in hemophilia A.16d ago

Similar companies

Ascendis Pharma A/SASND Metis Techbio-p07666.HK Jazz Pharmaceuticals plcJAZZ 康希诺688185.SH Shanghai Junshi Biosciences Co., Ltd.01877.HK Xcell Therapeutics, Inc.373110.KQ Find similar companies →

Latest newsMore news →

SinoCell Technologies reported a net loss of 366 million yuan for the first half of 2026, compared with a loss of 33.77 million yuan in the same period of 2025.7d ago Sinocelltech's controlled subsidiary Sinocelltech Engineering received approval from China's National Medical Products Administration to conduct clinical trials for its SCTB10 injection in hemophilia A.16d ago